InMed Pharmaceuticals Inc. (MTRI) stock
Close on Nov 11, 2026Market cap $85.75MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $85.75M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.16M
- EPS, diluted
- -$2.90
- Book value per share
- -$0.22
- Diluted shares
- 5M
Trading
- Previous close
- $12.20
- Open
- $12.50
- Day's range
- $12.50 – $16.50
- Volume
- 60,107
- Average volume (20 days)
- 17,708
- Beta (5 years)
- 2.18
- 52-week range
- $5.70 – $23.30
- RSI (14 days)
- 53.0
- Volatility (1 year)
- 160.5%
- Relative volume
- 0.88×
- WACC
- 15.8%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MTRI | S&P 500 | Difference | MTRI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.8% | -2.4% | +17.2 pts | ||
| 3 months | +6.9% | -1.2% | +8.1 pts | ||
| Year to date | +47.3% | +12.3% | +35.0 pts | ||
| 1 year | -10.3% | +12.4% | −22.7 pts | ||
| 3 years | -79.9% | +78.8% | −158.7 pts | -41.5% | +21.4% |
| 5 years | -99.8% | +75.2% | −174.9 pts | -70.3% | +11.9% |
Eight years at a glance
Fiscal years 2019 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases InMed Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- News
- Update
- News
About InMed Pharmaceuticals
Pharmaceutical Preparations
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company engaged in the research and preclinical development of proprietary small molecule drug candidates. The company focuses on developing preferential signaling ligands targeting cannabinoid CB1 and CB2 receptors and other disease-related pathways. Its research pipeline includes INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755 cannabinol cream for epidermolysis bullosa and itch-related conditions. InMed previously operated a commercial operations segment through BayMedica, which constituted its sole revenue-generating unit before being completely wound down. The company aims to advance its pipeline toward clinical trials and pursue licensing or commercial partnerships.
Company profile, executives and historyInMed Pharmaceuticals stock: common questions
What is InMed Pharmaceuticals's stock price?
MTRI closed at $15.61 on Nov 11, 2026, up 27.94% on the day. Over the past 52 weeks it traded between $5.70 and $23.30.
What is InMed Pharmaceuticals's market cap?
InMed Pharmaceuticals was worth $85.75M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MTRI's P/E ratio?
InMed Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.90), so it has no meaningful P/E ratio.
Does InMed Pharmaceuticals pay a dividend?
No. InMed Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has MTRI stock performed over the past year?
Including dividends, MTRI returned -10.3% over the past year, against +12.4% for the S&P 500.
Who are InMed Pharmaceuticals's competitors?
Companies most similar to InMed Pharmaceuticals by business, industry and size include ANL, TRDA, COYA, IVA, IMNM.
See a number that looks wrong?